(Press-News.org) LOS ANGELES — The herpes simplex virus type 1 (HSV-1), which affects almost two-thirds of the world’s population and is generally associated with oral herpes, may cause painful cold sores or fever blisters around the mouth.
Yet, when genetically engineered to fight cancer, the virus may also play an important role in treating advanced melanoma, skin cancer that has spread to other parts of the body, according to phase 1-2 clinical trial results published in the Journal of Clinical Oncology and recently presented by Keck Medicine of USC at the 2025 American Society of Clinical Oncology annual meeting.
The study involved 140 patients from the IGNYTE clinical trial, which included Keck Medicine and other sites worldwide. These patients had advanced melanoma that did not respond or stopped responding to immunotherapy, which uses the body’s own immune system to fight cancer.
Patients were treated with a genetically modified HSV-1 in combination with an immunotherapy (nivolumab). By the end of the clinical trial, one-third of the participants had their tumors shrink by at least 30%, and nearly one out of six patients had tumors completely disappear.
“These findings are very encouraging because melanoma is the fifth most common cancer for adults, and about half of all advanced melanoma cases cannot be managed with currently available immunotherapy treatments,” said Gino Kim In, MD, a medical oncologist with Keck Medicine and principal investigator at the Keck Medicine clinical trial site. Dr. In is also a member of the IGNYTE trial steering committee and one of the lead investigators on the trial. “The survival rate of untreatable advanced melanoma is only a few years, so this new therapy offers hope to patients who may have run out of options to fight the cancer.”
A novel class of drugs to fight cancer
The genetically modified HSV-1 evaluated in the study, RP1, is one of a relatively new, innovative class of cancer immunotherapy drugs known as oncolytic viruses that are designed to target and destroy cancer tumors while generating an anti-tumor immune response throughout the entire body. RP1 does not cause herpes.
In January 2025, the U.S. Food and Drug Administration granted priority review to RP1 with nivolumab for patients with advanced melanoma whose cancer had not responded to prior immunotherapy.
When injected into a tumor, RP1 replicates, killing off the cancer cells while leaving healthy cells unharmed. Additionally, RP1 stimulates the body’s white blood cells to seek out and destroy any other cancer cells in the body.
The second cancer drug used in the study, nivolumab, is a standard immunotherapy treatment in fighting advanced melanoma and other cancers that have spread through the body. Researchers theorized that nivolumab, which works by using the body’s own immune system to fight and destroy cancer cells, would enhance the potential effect of RP1.
How the treatment was administered
Patients admitted into the study had already been treated with minimal success by one or more immunotherapy therapies and had to have more than one tumor that could be injected with RP1. Some tumors were considered “superficial” — meaning visible on the skin, or just below the skin’s surface — and some were located deeper in the body, such as in the liver or lungs. Researchers injected both superficial and deep tumors with RP1.
Encouraging Findings
During the clinical trial, patients were given a combined therapy of RP1 and nivolumab every two weeks for up to eight cycles. If patients responded to the treatment, they continued on nivolumab alone every four weeks for up to 30 cycles (or two years).
Researchers measured both treated tumors and untreated tumors. They discovered that not only did injected tumor size shrink in one third of the patients by 30%, but that patients’ uninjected tumors also shrank or even disappeared, just as frequently and as deeply.
“This result suggests that RPI is effective in targeting cancer throughout the entire body and not just the injected tumor, which expands the potential effectiveness of the drug because some tumors may be more difficult or impossible to reach,” said Dr. In, who is also a member of USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC.
The study also found that RP1 was well-tolerated and had a favorable safety outcome.
While it is too soon to tell if the positive outcomes remain permanent, Dr. In is optimistic about the future of RP1 therapy. “I believe that oncolytic viruses will open up an important new approach to fighting cancer in some patients in the near future,” he said.
Other clinical trial researchers include Phillip M. Cheng, MD and Ali Rastegarpour, MD, diagnostic radiologists with Keck Medicine.
Phase 3 clinical trial now open
Phase 1-2 of the IGNYTE clinical trial examined the safety, side effects, best dosing and effectiveness of administering RP1 along with nivolumab on a limited patient population. Dr. In and his fellow researchers have launched the phase 3 trial, known as IGNYTE-3, to confirm their findings in a global population of more than 400 participants.
Keck Medicine will again be one of the sites of the clinical trial, with Dr. In heading up the site. Patients interested in participating can contact Sandy Tran at sandy.tran@med.usc.edu.
Replimune, a manufacturer of RP1 and other oncolytic immunotherapies, is the sponsor of the IGNYTE clinical trial
Disclosure: In Dr. In’s role as a member of the steering committee for the IGNYTE clinical trial, he has served on advisory boards for the sponsoring company and received honoraria.
###
For more information about Keck Medicine of USC, please visit news.KeckMedicine.org.
END
Cancer-fighting herpes virus shown to be an effective treatment for some advanced melanoma
A genetically engineered herpes simplex virus, when combined with immunotherapy, reduces or eliminates tumors in one-third of clinical trial patients, according to new study
2025-07-08
ELSE PRESS RELEASES FROM THIS DATE:
Eliminating invasive rats may restore the flow of nutrients across food chain networks in Seychelles
2025-07-08
Ecosystems are characterized by interconnected structure and functions. A study published July 8th in the open-access journal PLOS Biology by Casey Benkwitt at Lancaster University, United Kingdom and colleagues suggests that restoring seabird populations via eradication of rats may help coral reefs by restoring nutrient connectivity in disrupted food chains.
Invasive rats in the Seychelles have decreased native seabird populations. However, the mechanism by which seabirds may impact coral reef ecosystem structure ...
World’s first: Lithuanian scientists’ discovery may transform OLED technology and explosives detection
2025-07-08
In modern devices, such as phone screens or advanced sensors, light is often generated by pairs of organic molecules, where one molecule, known as the donor, transmits electrons, and the other, referred to as the acceptor, receives them. An international team of scientists from Kaunas University of Technology, KTU, Lithuania, has, for the first time, observed the luminescence of an excited complex formed by two donor molecules. This discovery opens new possibilities for developing simpler, more efficient, and more sustainable optoelectronic devices.
“Until now, such interactions were considered practically impossible. This discovery challenges the fundamental principles we have used ...
Rice researchers develop superstrong, eco-friendly materials from bacteria
2025-07-08
HOUSTON – (July 8, 2025) – Scientists at Rice University and University of Houston have developed an innovative, scalable approach to engineer bacterial cellulose into high-strength, multifunctional materials. The study, published in Nature Communications, introduces a dynamic biosynthesis technique that aligns bacterial cellulose fibers in real-time, resulting in robust biopolymer sheets with exceptional mechanical properties.
Plastic pollution persists because traditional synthetic polymers degrade into microplastics, releasing harmful chemicals like bisphenol ...
Itani studying translation potential of secure & efficient software updates in industrial internet of things architectures
2025-07-08
Itani Studying Translation Potential Of Secure & Efficient Software Updates In Industrial Internet of Things Architectures
Wassim Itani, Associate Professor, Computer Science, College of Engineering and Computing (CEC), received funding for the project: “I-Corps: Translation Potential of Secure and Efficient Software Updates in Industrial Internet of Things Architectures (IIoT).”
He is addressing several critical challenges, including limited computing and network resources of IIoT devices, lack of operational and security standards, absence of a cryptographic root of trust, unique operational requirements of IIoT ...
Elucidating the source process of the 2021 south sandwich islands tsunami earthquake
2025-07-08
Tsukuba, Japan—Tsunami earthquakes are characterized by the generation of disproportionately large tsunamis relative to the observed ground shaking, complicating timely evacuation efforts. Understanding their generation mechanisms and associated risks is therefore critical. One proposed cause is slow, uniform fault slip facilitated by soft sedimentary layers in the source region; however, this mechanism remains poorly understood. Additionally, the seismic signals from tsunami earthquakes are often too complex to be explained by conventional models, and their source processes have not been fully clarified.
In this study, the research team analyzed seismic waveform data from ...
Zhu studying use of big data in verification of route choice models
2025-07-08
Zhu Studying Use Of Big Data In Verification Of Route Choice Models
Shanjiang Zhu, Associate Professor, Civil, Environmental, and Infrastructure Engineering, College of Engineering and Computing (CEC), received funding for the study: “Utilizing Big Data to Verify and Enhance Route Choice Models in Travel Demand Modeling.”
Connected vehicle data has attracted a lot of interest from transportation professionals, but researchers are still exploring the best way to use it. This research effort will determine the best way to use connected vehicle data to enhance accuracy of travel demand models. It will challenge the conventional ...
Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA study finds
2025-07-08
A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor–induced type 1 diabetes, a rare but life-threatening side effect of cancer immunotherapy, using an existing class of autoimmune drugs.
The study, published in JCI Insight, identifies a new group of immune cells involved in the development immune checkpoint inhibitor–induced type 1 diabetes and shows that JAK inhibitors, which are already ...
Quantum battery device lasts much longer than previous demonstrations
2025-07-08
Researchers from RMIT University and CSIRO, Australia’s national science agency, have unveiled a method to significantly extend the lifetime of quantum batteries – 1,000 times longer than previous demonstrations.
A quantum battery is a theoretical concept that emerged from research in quantum science and technology.
Unlike traditional batteries, which rely on chemical reactions, quantum batteries use quantum superposition and interactions between electrons and light to achieve faster charging times and potentially enhanced storage capacity.
In ...
Gamma knife stereotactic radiosurgery for brain metastases from ovarian cancer
2025-07-08
Background and objectives
Brain metastases from ovarian cancer (BMFOC) are rare but associated with poor prognosis. This study aimed to evaluate the efficacy and safety of Gamma Knife stereotactic radiosurgery (GKSRS) in managing patients with BMFOC.
Methods
A retrospective analysis was conducted on 22 patients with BMFOC who were treated with GKSRS between January 2015 and May 2019. The median age at the start of treatment was 57.7 years (range, 46–72 years). A total of 70 brain metastases were treated, with ...
Meet the “plastivore” caterpillars that grow fat from eating plastic
2025-07-08
Plastics play a fundamental role in modern life, but their resistance to biodegradation makes them very difficult to dispose of. New research reveals how “plastivore” caterpillars can metabolically degrade plastics in a matter of days, not decades, and store them internally as body fat – but at what cost?
In 2017, a groundbreaking study demonstrated that the caterpillars of the greater wax moth (Galleria mellonella), known as waxworms, can degrade polyethylene plastic. Polyethylene is the world’s most commonly manufactured plastic, with ...
LAST 30 PRESS RELEASES:
New mathematical insights into Lagrangian turbulence
Clinical trials reveal promising alternatives to high-toxicity tuberculosis drug
Artificial solar eclipses in space could shed light on Sun
Probing the cosmic Dark Ages from the far side of the Moon
UK hopes to bolster space weather forecasts with Europe's first solar storm monitor
Can one video change a teen's mindset? New study says yes - but there’s a catch
How lakes connect to groundwater critical for resilience to climate change, research finds
Youngest basaltic lunar meteorite fills nearly one billion-year gap in Moon’s volcanic history
Cal Poly Chemistry professor among three U.S. faculty to be honored for contributions to chemistry instruction
Stoichiometric crystal shows promise in quantum memory
Study sheds light on why some prostate tumors are resistant to treatment
Tree pollen reveals 150,000 years of monsoon history—and a warning for Australia’s northern rainfall
Best skin care ingredients revealed in thorough, national review
MicroRNA is awarded an Impact Factor Ranking for 2024
From COVID to cancer, new at-home test spots disease with startling accuracy
Now accepting submissions: Special Collection on Cognitive Aging
Young adult literature is not as young as it used to be
Can ChatGPT actually “see” red? New results of Google-funded study are nuanced
Turning quantum bottlenecks into breakthroughs
Cancer-fighting herpes virus shown to be an effective treatment for some advanced melanoma
Eliminating invasive rats may restore the flow of nutrients across food chain networks in Seychelles
World’s first: Lithuanian scientists’ discovery may transform OLED technology and explosives detection
Rice researchers develop superstrong, eco-friendly materials from bacteria
Itani studying translation potential of secure & efficient software updates in industrial internet of things architectures
Elucidating the source process of the 2021 south sandwich islands tsunami earthquake
Zhu studying use of big data in verification of route choice models
Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA study finds
Quantum battery device lasts much longer than previous demonstrations
Gamma knife stereotactic radiosurgery for brain metastases from ovarian cancer
Meet the “plastivore” caterpillars that grow fat from eating plastic
[Press-News.org] Cancer-fighting herpes virus shown to be an effective treatment for some advanced melanomaA genetically engineered herpes simplex virus, when combined with immunotherapy, reduces or eliminates tumors in one-third of clinical trial patients, according to new study